Actively Recruiting
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants
Led by Eli Lilly and Company · Updated on 2026-03-03
104
Participants Needed
1
Research Sites
120 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of this study is to explore the safety and any side effects of LY4066708 in healthy participants. The study will also measure how much LY4066708 gets into the bloodstream and the central nervous system and how long it takes the body to remove it. The study will last up to 24 weeks for each participant.
CONDITIONS
Official Title
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be overtly healthy as confirmed by medical evaluation including history, physical exam, lab tests, and cardiac monitoring.
- Japanese participants must have exclusive Japanese descent for themselves, their parents, and grandparents born in Japan.
- Chinese participants must have all four grandparents of exclusive Chinese descent born in China, Hong Kong, Macau, or Taiwan.
- Body Mass Index (BMI) must be between 18.5 and 30 kg/m² at screening.
- Participants assigned female at birth not of childbearing potential and participants assigned male at birth willing to use effective contraception throughout the study may participate.
- Willingness to undergo study procedures including repeated lumbar punctures.
You will not qualify if you...
- Individuals of childbearing potential are excluded; participants assigned female at birth who are breastfeeding are also excluded.
- History of risk factors for Torsades de Pointes, such as heart failure, hypokalemia, or family history of Long QT Syndrome.
- Use of medications that prolong the QT/QTc interval.
- Known allergies to LY4066708 or any transferrin receptor antibodies.
- Participation in another clinical trial involving an investigational product within 3 months prior to screening (or 5 half-lives if applicable).
- Previous completion or withdrawal from this study after receiving the study intervention (except those allowed to rescreen).
- ECG abnormalities at screening that increase risk or may affect ECG data.
- Evidence or history of hepatitis C infection.
- Current or past infection with hepatitis B virus as indicated by positive tests.
- Marked baseline prolongation of QT/QTc interval (e.g., QTcF > 450 ms).
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fortrea Clinical Research Unit
Holbeck, Leeds, United Kingdom, LS11 9EH
Actively Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
P
Physicians interested in becoming principal investigators please contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
15
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here